Genprex Inc

GNPX

Company Profile

  • Business description

    Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex’s oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company’s product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

  • Contact

    3300 Bee Cave Road
    Suite 650-227
    AustinTX78746
    USA

    T: +1 877 774-4679

    https://www.genprex.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    13

Stocks News & Analysis

stocks

Is this ASX share a value trap or bargain?

Cost-cutting the priority as underlying asset values falling on deaf ears.
stocks

Goldman Sachs Earnings: Valuations remain stretched

We raise our fair value estimate for Goldman Sachs stock.
stocks

Major ASX listed miners overvalued

We’ve adjusted our fair values after updating our commodity price assumptions.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,138.6019.70-0.22%
CAC 408,062.5849.44-0.61%
DAX 4024,703.12255.94-1.03%
Dow JONES (US)48,497.96861.37-1.75%
FTSE 10010,126.7868.57-0.67%
HKSE26,487.5176.39-0.29%
NASDAQ22,986.21529.18-2.25%
Nikkei 22552,991.10592.47-1.11%
NZX 50 Index13,573.936.36-0.05%
S&P 5006,804.00136.01-1.96%
S&P/ASX 2008,815.9020.70-0.23%
SSE Composite Index4,113.650.35-0.01%

Market Movers